Endothelial dysfunction has been implicated in the pathophysiology of different forms of cardiovascular disease, including hypertension. It may be defined as impairment characterized by a shift of the actions of the endothelium toward reduced vasodilation, a proinflammatory state, and prothrombotic setting. These events lead to a state of vascular inflammation, which may be mediated, partly, by ROS formed by activated mononuclear cells.

Oxidative stress constitutes a unifying mechanism of injury of many types of disease processes, it occurs when there is an imbalance between the generation of ROS and the antioxidant defense systems in the body. The ROS family comprises many molecules that have divergent effects on cellular function. Importantly, many of these actions are associated with pathological changes observed in cardiovascular disease. The effects of ROS are mediated through redox-sensitive regulation of multiple signaling molecules and second messengers[5-7]. Several studies have demonstrated that essential hypertensive patients and various animal models of hypertension produce excessive amount of ROS[8-12], and have abnormal levels of antioxidant status[13], thereby contributing to the accumulating evidence that increased vascular oxidative stress could be involved in the pathogenesis of essential hypertension[2,3,14]. Recently, it was demonstrated a strong association between blood pressure and some oxidative stress-related parameters[15]. Other studies show that mouse models with genetic deficient in ROS-generating enzymes have lower blood pressure compared with wild-type counterparts[16,17]. In addition, in cultured vascular smooth muscle cells (VSMC) and isolated arteries from hypertensive rats and humans, ROS production is enhanced, redox-dependent signaling is amplified, and antioxidant bioactivity is reduced[18]. Classical antihypertensive agents such as β-adrenergic blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor antagonists, and calcium channel blockers may be mediated, in part, by decreasing vascular oxidative stress[19,20].

A variety of enzymatic and non-enzymatic sources of ROS exist in blood vessels. The best characterized source of ROS is NOX. In addition to NOX, several other enzymes may contribute to ROS generation, including xanthine oxidase, NO synthase and the mitochondrion.

NOX: NOX is the primary biochemical source of ROS in the vasculature, particularly of superoxide. The kidney and vasculature are rich sources of NOX-derived ROS, which under pathological conditions play an important role in renal dysfunction and vascular damage[12,21]. This system catalyses the reduction of molecular oxygen by NADPH as electron donor, thus generating superoxide. NOX is up-regulated in hypertension by humoral and mechanical signals. AT-II is the most studied stimulus, but ET-1 and UT-II may also participate in activation of NOX, thereby resulting in increased ROS. Likely the most well-known function of NOX derived superoxide is inactivation of NO to form peroxynitrite, leading to impaired endothelium dependent vasodilation and uncoupling of endothelial nitric oxide synthase (eNOS) to produce additional superoxide[16,22]. In the vasculature, NOX activation has been strongly associated with hypertension[23].

Uncoupled endothelial NO synthase: The primary function of eNOS is NO production which regulates vasodilation. Nevertheless, L-arginine and tetrahydrobiopterin (BH₄)-two essential cofactors for its action-deficiency or oxidation are associated with uncoupling of the L-arginine-NO pathway resulting in decreased formation of NO, and increased eNOS-mediated generation of superoxide. NOX is the initial source of ROS. Superoxide combines with NO, which is synthesized by eNOS, to form peroxynitrite[24]. In turn, peroxynitrite oxidizes and destabilizes eNOS to produce more superoxide[22,25]. Superoxide also leads to BH₄ oxidation (in fact, BH₄ is highly sensitive to oxidation), which promotes eNOS uncoupling and ROS production.

Xanthine oxidase: Xanthine oxidase is also an important source for oxygen free radical present in the vascular endothelium[23,26]. It catalyzes the last two steps of purine metabolism. During this process oxygen is reduced to superoxide. There is evidence suggesting involvement of this enzyme in hypertension. Spontaneously hypertensive rats demonstrate elevated levels of endothelial xanthine oxidase and increased ROS production, which is associated with increased arteriolar tone[21]. In addition to effects on the vasculature, xanthine oxidase may play a role in end-organ damage in hypertension[27].

Mitochondrion: The mitochondrion is a major source and target of ROS. Part of the superoxide produced in the intermembrane space may be carried to the cytoplasm[28]. Ubiquinol or coenzyme Q is a source of superoxide when partially reduced (semiquinone form) and an antioxidant when fully reduced[29]. Complex I produces most of the superoxide generated by mammalian mitochondria in vitro. Complexes II and IV are not normally significant sites of ROS production. Mild uncoupling very effectively decreases the high superoxide production that occurs from complex I. A reduction in antioxidant enzymatic activity in patients with hypertension has been reported[30].

The endothelium senses mechanical and hormonal stimuli. In response, it releases agents that regulate vasomotor function. There is no doubt that endothelium plays a regulatory and protective role by generating vasorelaxing substances. Under some pathophysiological circumstances, endothelium derived vasoconstricting factors, such as ET-1, AT-II, UT-II, superoxide anions, vasoconstrictor prostaglandins and thromboxane A₂, can be released and contribute to the paradoxical vasoconstrictor effects. VSMC are fit not only for short-term regulation of the blood vessel diameter and therefore of blood pressure, but also for long-term adaptation, via structural remodeling. ROS mediate many of these pathophysiological processes. The adventitia can contribute to hypertension by either reducing NO bioavailability or participating in vascular remodeling through ROS.

NO: NO is known to play an important role as a key paracrine regulator of vascular tone. Physiologically, NO inhibits leukocyte-endothelial cell adhesion, VSMC proliferation and migration, and platelet aggregation to maintain the health of the vascular endothelium. Therefore it has many beneficial effects. The decrease in bioavailability of NO in the vasculature reduces vasodilatory capacity and contributes to hypertension. The enzyme that catalyzes the formation of NO from oxygen and arginine is NOS, which in fact is a whole family of enzymes. eNOS is the predominant NOS isoform in the vessel wall. Receptor-mediated agonist stimulation leads to rapid enzyme activation. In addition, shear stress and allosteric modulators are also an important modulator of eNOS activity[31]. Except the vasorelaxing and antiproliferative properties per se, NO plays an important role in antagonizing the effects of AT-II, endothelins and ROS. Nitric oxide diffuses as a gas to the adjacent smooth muscle where it interacts with different receptor molecules such as the soluble guanylyl cyclase. It is accepted that the normal production of NO plays a crucial role in the maintenance of the physiologic conditions within the cardiovascular system. L-arginine, a substrate for eNOS, seems to be promising in preserving NO formation. However, L-arginine failed to prevent blood pressure increase and left ventricle remodeling due to chronic treatment with L-methyl ester of N-nitro-L-arginin (NAME), an inhibitor of eNOS[32]. The ACE inhibitor captopril completely prevented NO-deficient hypertension, yet without improving NOS activity. NO also has an ACE down-regulation effect. Thiols protect NO from oxidation by scavenging oxygen-free radicals and by forming nitrosothiols, both effects prolonging NO half-life and duration of NO action[33,34]. Reduced NO levels can be attributed to elevated levels of ROS. Superoxide combines with NO to form peroxynitrite that oxidizes BH₄ and destabilizes eNOS to produce more superoxide[22,24,25] thus further enhancing the development of oxidative stress. The balance between NO and AT-II in the vasomotor centers seems to play important role in the regulation of the sympathetic tone.

Renin-angiotensin system: The renin-angiotensin system plays a key role in the development of cardiovascular disease. AT-II is a potent vasoactive peptide that can be formed in vascular beds rich in ACE. When AT-II production increases above normal levels, it induces vascular remodeling and endothelial dysfunction in association with increases in levels of blood pressure. As a potent activator of NOX, AT-II contributes to the production of ROS[35,36]. In rats and mice made hypertensive by AT-II infusion, expression of NOX subunits, oxidase activity, and generation of ROS are all increased[37]. AT-II not only increases NOX activity but also upregulates superoxide dismutase activity, possibly to compensate for the increased ROS. In situations where this compensatory effect is efficient, ROS levels may appear normal even in the face of prooxidant. However, when ROS production becomes overwhelming, compensatory mechanisms are inadequate and pathophysiological consequences ensue[38]. Captopril and enalapril prevented blood pressure rise in young spontaneously hypertensive rats inhibiting ACE. Captopril, probably due to the antioxidant role of its thiol group, had more effective hypotensive effect than enalapril[39,40]. In contrast, NO not solely antagonizes the effects of AT-II on vascular tone, cell growth, and renal sodium excretion, but also down-regulates the synthesis of ACE and AT₁ receptors. On the other hand, ACE inhibition up-regulates eNOS expression. The ability of AT-II to induce endothelial dysfunction is also due to its ability to down-regulate soluble guanylyl cyclase, thereby leading to impaired NO/cGMP signaling. Recently, it has been proposed that Ca²⁺/calmodulin-dependent protein kinase II is an important molecule linking AT-II, ROS and cardiovascular pathological conditions[41].

Acetylcholine: In vascular vessels, acetylcholine induces endothelium-dependent dilation via production of endothelial factors, mainly NO. NO then diffuses to underlying VSMC, where it induces vascular smooth muscle cell relaxation. The diminution in NO bioavailability will lead to significantly reduced acetylcholine-mediated vasodilation[39,40]. The consequence of an overall increase in ROS is a reduce bioavailability of NO.

ET-1: Endothelins are potent vasoconstrictor isopeptides produced in different vascular tissues, including vascular endothelium. ET-1 is the main endothelin generated by the endothelium and the most important in the cardiovascular system. When ET-1 is administered in large concentrations, it behaves as a potent vasoconstrictor capable of exerting an array of physiological effects, including the potential to alter arterial pressure. ET-1 mediates its effects through two receptors, ET_A and ET_B. ET_A mediates contractions via activation of NOX, xanthine oxidase, lipoxygenase, uncoupled NO synthase, and mitochondrial respiratory chain enzymes. The ET_B induces relaxation on endothelial cells[42]. Many factors that normally stimulate ET-1 synthesis, (e.g., thrombin, AT-II) also cause the release of vasodilators such as prostacyclin (PGI₂) and/or NO, which oppose the vasoconstricting action of ET-1. It was reported that essential hypertension is characterized by increased ET-1 vasoconstrictor tone, an effect that seems to be dependent on decreased endothelial ET_B-mediated NO production attributable to the impaired NO bioavailability.

UT-II: UT-II is a potent vasoactive peptide[43], indeed the most potent vasoconstrictor identified. It acts trough activation of NOX. The role of UT-II in disease is not well elucidated. The constrictor response to UT-II appears to be variable and highly dependent on the vascular bed examined. Vasoconstriction is not its only effect, because UT receptors have been found in other organs[44,45]. UT-II has also been shown to act as a potent vasodilator in some isolated vessels[46].

Norepinephrine: VSMC is innervated primarily by the sympathetic nervous system through adrenergic receptors. Three types of adrenoceptors are present within VSMC: α1, α2 and β2. Norepinephrine stimulates VSMC proliferation. In addition, over-expression of inducible NOS increases blood pressure via central activation of the sympathetic nervous system, which is mediated by an increase in oxidative stress[5].

Prostaglandins: PGI₂, another endothelium-dependent vasodilator, relaxes the VSMC. PGI₂ is released in higher amount in response to ligand binding such as thrombin, arachidonic acid, histamine, or serotonin. The enzymes prostaglandin H₂ synthase uses arachidonic acid as a substrate, forming prostaglandin H₂. Prostaglandin H₂ is converted to vasoactive molecules, such as PGI₂. The isoform prostaglandin H₂ synthase-2 may mediate vascular dysfunction in conditions characterized by oxidative stress. Thus, peroxynitrite inhibits the enzymatic activity of prostacyclin synthase, thereby causing impairment in the PGI₂-mediated vasodilation.

Homocysteine: This molecule may play an important role in the pathogenesis of essential hypertension[3]. Elevated homocysteinemia diminishes the vasodilation by nitric oxide, increases oxidative stress, stimulates the proliferation of VSMC, and alters the elastic properties of the vascular wall. Thus, homocysteine contributes to elevate the blood pressure[47]. It is also known that elevated homocysteine levels could lead to oxidant injury of the endothelium[3]. The correction of elevated homocysteinemia by administration of vitamins B12 and B6 plus folic acid, could be a useful adjuvant therapy of hypertension[3,48]. However, further controlled randomized trials are necessary to establish the efficacy of these therapeutic agents.

A hypothesis for the role of vascular oxidative stress in hypertension is depicted in Figure 1.

Open in New Tab   Full Size Figure   Download Figure

Figure 1 Schematic summary of the role of vascular oxidative stress in the pathogenesis of hypertension and the mechanisms of exogenous antioxidant accounting for anti-hypertensive effects. AT-II: Angiotensin II; AT₁R: Type 1 angiotensin II receptor; ET-1: Endothelin 1; ET_AR: Type A endothelin receptor; UT-II: Urotensin II; UTR: Urotensin-II receptor; NO: Nitric oxide; eNOS: Endothelial nitric oxide synthase; PGI₂: Prostacyclin; NAC: N-Acetylcysteine; NOX: NADPH oxidase; NF-κB: Nuclear factor kappa B.

This review has discussed the importance of ROS in the vasculature and its relation to hypertension, but it is important to emphasize the evidence that hypertensive stimuli, such as high salt and AT-II, promote the production of ROS not only in the vasculature, but also in kidney and the central nervous system (CNS) and that each of these sites contributes either to hypertension or to the untoward sequels of this disease[48].

Evidence proposes that ROS play a key role in the pathophysiological processes of several renal diseases; these diseases are considered to be cause and consequence of hypertension. Regarding glomerular alterations, ROS mediates lipoprotein glomerulopathy and other inflammatory glomerular lesions[49]. A recent study demonstrates that NOX activation and production of ROS through lipid raft clustering is an important molecular mechanism triggering oxidative injury of podocytes induced by homocysteine. This may represent an early event initiating glomerulosclerosis during hyperhomocysteinemia[50]. Concerning ROS mediated tubulointerstitial injury, one of the mechanisms is the exposure of tubular cells to low-density lipoproteins which may result in tubulointerstitial damage due to ROS production mediated by NOX[51]. AT-II also plays a pivotal role in the progression of tubulointersitial injury but also in obstructive nephropathy[52,53]. It activates NOX and, subsequently, generates superoxide that leads to hypertrophy of renal tubular cells[54].

There is evidence suggesting that a high-fat diet induces renal inflammation and aggravation of blood pressure in spontaneously hypertensive rats, via ROS[55]. It is also known that the metabolic syndrome is a risk factor for chronic kidney disease (CKD) at least in part independent of diabetes and hypertension per se, probably mediated by ROS. Moreover, the onset and maintenance of renal damage may worsen metabolic syndrome features like hypertension, leading to potential vicious cycles[56].

There are several oxidative stress-mediated mechanisms involved in endothelial dysfunction in CKD[57]. ROS are elevated in CKD and related to endothelium-dependent vascular reactivity and systolic blood pressure[58]. High ROS and increased level of the endogenous asymmetric dimethylarginine (ADMA) was reported to be a novel risk factor for endothelial dysfunction[59]. Moreover, high levels of ADMA were reported in CKD and were associated with higher intima-media thickness and cardiovascular events[60]. In renovascular hypertension, oxidative stress in the ischemic kidney plays a major role in the maintenance of hypertension in two kidney-one clip rats[61].

Just like the kidney and the vasculature itself, the sympathetic nervous system (SNS), regulated in the CNS, plays an important role in the pathogenesis of hypertension[62]. Recent studies strongly suggest that central sympathetic outflow is increased in hypertension[63]. There is also evidence that increased ROS generation in the brainstem contributes to the neural mechanisms of hypertension in hypertensive rats[64].

The rostral ventrolateral medulla (RVLM) is the major vasomotor center and is essential for the maintenance of basal vasomotor tone[65,66]. There are findings that strongly indicate that ROS in the RVLM is increased in stroke-prone spontaneously hypertensive rats and thereby contributes to the neural mechanisms of hypertension through activation of the SNS[65]. The paraventricular nucleus of the hypothalamus is most likely also involved in the ROS mediated neural mechanism of hypertension[61,67]. There is evidence that other regions of the brain are also involved in ROS mediated hypertension. These investigations suggest that increased intracellular superoxide production in the subfornical organ is critical in the development of AT-II-induced hypertension[68].

This section refers to the antihypertensive role of endogenous and exogenous antioxidants that have demonstrated their ability to alter the blood vessels function and to participate in the main redox reactions involved in the pathophysiology of hypertension.

Vitamin C: Vitamin C is a potent water-soluble antioxidant. On the vascular wall behaves as enzyme modulator exerting up-regulation on eNOS and down regulation of NOX[69]. Most studies have demonstrated an inverse relationship between plasma ascorbate levels and blood pressure in both normotensive and hypertensive populations[15]. It has been shown that treatment with antioxidants improves the vascular function and reduces the blood pressure in animal models[70,71] and in human hypertension[72,73]. Vitamin C may have favorable effects on vascular dilation, possibly through its antioxidant effects on NO[74-76].

Nevertheless, there are several small and short-term clinical trials in which the effect of vitamin C supplements on blood pressure have yielded inconsistent findings[77-82]. The lack of antihypertensive efficacy observed in studies using supplementation with vitamin C alone could be due to the decreased bioavailability of NO under conditions of oxidative stress. It was shown that these effects are mediated in part by the ability of vitamin C to protect BH₄ from oxidation and thereby increase the enzymatic activity of eNOS[83]. In addition, this uncertain clinical beneficial effect of vitamin C in vivo as an antihypertensive agent could be due to the lack of consideration of their pharmacokinetic properties. It was experimentally determined that the antihypertensive effect of vitamin C is expected to occur at a concentration by 10μmo/L[75], a plasma level unreachable in humans through oral administration, but that would be required to compete efficiently with the reaction of NO with superoxide. The renal ascorbic acid threshold occurs at vitamin C dose between 60 and 100 mg daily. Plasma is completely saturated at doses of 400 mg daily and higher, producing a steady-state plasma concentration of approximately 80 μmo/L[84]. Thus, the antihypertensive effect may only be active in plasma following vitamin C infusion at high doses.

Vitamin E: This major lipid-soluble antioxidant has received considerable attention for their antioxidant potential. Epidemiological data support a role of high dietary vitamin E intake and a reduced incidence of cardiovascular disease[57]. Increasing evidence indicates that vitamin E can act as a biological modifier independently of its antioxidant activity. Experimental evidence available shows that vitamin E is capable of dose-dependently regulating mitochondrial generation of superoxide and hydrogen peroxide.

However, intervention trials have not been convincing, with a number of studies demonstrating no beneficial effect of vitamin E on cardiovascular disease outcomes[85-88]. Moreover, a study using supplementation with vitamin E, either as α-tocopherol or mixed tocopherols, showed a significant increase in blood pressure, pulse pressure and heart rate in individuals with type 2 diabetes[89]. It should be noted that it is unlikely to achieve sufficiently high concentrations in the vascular microenvironment to interfere effectively with all components of oxidative stress[90].

Association of vitamins C and E: Ascorbic acid may reduce the α-tocopheroxyl radical and may be required for beneficial vascular effects of α-tocopherol[91]. In fact, the effect of α-tocopherol seems to be dependent on tissue saturation with vitamin C, and both vitamins may act synergistically to provide optimal conditions for endothelial NO formation[92]. Thus, the association of vitamins C and E is expected to have an antihypertensive effect probably because this combined therapy provides a reinforcement of their individual properties through a complementary effect[93].

Despite the biological effects of both vitamin C and E, long-term clinical trials have failed to consistently support their antihypertensive effects in patients at high cardiovascular risk. Some short-term trials have shown that supplemental antioxidant vitamin intake lowers blood pressure[78,81,82,94] but the majority of clinical long-term trials did not find any antihypertensive effects of antioxidant vitamins. However, most of these studies lack rigorous exclusion criteria in the selection of subjects to avoid the influence of confounders[95]. It deserves special mention that regarding cohorts included in large trials, most subjects had irreversible cardiovascular disease.

Allopurinol: Xanthine oxidase is an important source of ROS in the vascular endothelium[24]. It catalyzes the last two steps of purine metabolism, producing uric acid. Xanthine oxidase activity is associated with an increasing arteriolar tone and therefore, hypertension[96,97]. Xanthine oxidase inhibitors such as allopurinol have shown marked improvements in endothelial function in various cohorts at risk of cardiovascular events. Treatment with allopurinol result in reduction of blood pressure in adolescents[98], spontaneously hypertensive rats[99] and patients with CKD[100]. Nevertheless, most of the evidence so far comes from smaller mechanistic studies, and the few large randomized controlled trials have not shown significant mortality benefit using these agents[101].

Selenium: Selenium is an essential trace element and an integral part of many proteins with catalytic and structural functions. It exerts an antioxidant function mainly in the form of selenocysteine residues, an integral constituent of ROS-detoxifying selenoenzymes, such as glutathione peroxidase (GSH-Px), thioredoxin reductases (TR) and selenoprotein P[102]. Maintenance of full GSH-Px and TR activity by adequate dietary selenium supply has been proposed to be useful for the prevention of several cardiovascular disorders[83]. In addition, selenium is capable of preventing the union of nuclear factor kappa B (NF-κB) to its nuclear response elements in DNA[103]. NF-κB has a key role in inflammation and production of ROS. The inhibition of NF-κB is presumed to be the result of the binding of the selenium to the essential thiols of this transcription factor[104].

Its antioxidant properties have been documented in several trials[103,105-110]. Selenium at low doses can provide significant protection of the human coronary artery endothelium against damage by oxidative stress[102]. In an animal model, dietary supplementation with selenium was associated with lower levels of cardiac oxidative damage and increased antioxidant expression, as well as a reduction in disease severity and mortality in spontaneously hypertensive rats[111]. A reduced selenium concentration in hypertensive pregnancies has been associated with a diminution of GSH-Px activity[112]. Thus it is reasonable to say that deficiency of selenium might be an underestimated risk factor for the development of high blood pressure[113].

N-acetylcysteine: The antioxidant N-acetylcysteine (NAC), a sulfhydryl group donor, improves renal dysfunction and decreases arterial pressure and renal injury in salt-sensitive hypertension[114]. The inhibition of oxidative stress in hypertensive states probably contributes to the therapeutic effects of NAC, an effect likely mediated by an NO-dependent mechanism[115]. This protective mechanism is exerted by prevention of BH₄ oxidation by the increased superoxide[116]. In addition, this molecule can protect against oxidative damage inhibiting lipid peroxidation and scavenging ROS[117,118].

Polyphenols: Polyphenols are the most abundant antioxidant in diet. They can act as ROS scavengers, iron chelators, enzyme modulators[119,120], and possibly enhancing the production of NO[121,122]. In humans, after the consumption of polyphenols, circulating NO concentration increases[123]. Polyphenols also increase glutathione, and inhibit ROS-producing enzymes such as NADPH and xanthine oxidases. These pathways lead to improved endothelial function[124]. However, some studies have shown increased blood pressure by association of polyphenols with vitamin C[125].

Diet: There is sufficient evidence to suggest that dietary approaches may help to prevent and control high blood pressure. There are dietary approaches regarding the prevention and management of hypertension: i.e., moderate use of sodium, alcohol, an increased potassium intake, plant fibers, calcium, and foods like salmon, nuts, wine, among others[126]. In a Mediterranean population with an elevated fat consumption, a high fruit and vegetable intake is inversely associated with blood pressure levels[127]. Short-term studies indicate that specialized diets may prevent or ameliorate mild hypertension, most notable are the Dietary Approaches to Stop Hypertension (DASH) diet, which is high in fruits, vegetables, and low-fat dairy products[128]. It has been reported that a low sodium DASH diet is effective in reducing blood pressure in hypertensive patients, particularly in those taking antihypertensive medications[129]. In addition, DASH diet had significant beneficial effects on cardiovascular risk[130-132]. In overweight or obese persons with above-normal blood pressure, the addition of exercise and weight loss to the DASH diet resulted in even larger blood pressure reductions, greater improvements in vascular and autonomic function, and reduced left ventricular mass[133,134].

Recent advances in understanding the complexity of redox signaling in the vascular system points to a central role of oxidative stress in the pathogenesis of vascular dysfunction. This is how hypertension is associated with impaired endothelium-dependent vasodilation with inactivation of endothelium-derived nitric oxide by oxygen free radicals. In this regard, it has arisen a growing interest concerning the therapeutic possibilities to target ROS in the management of essential hypertension.

In support of this view, epidemiological studies suggest that individuals with higher antioxidant intake have reduced cardiovascular risk. In fact, population-based observational studies have shown an inverse association between diverse plasma antioxidant concentrations, obtained by dietary intake, with blood pressure[113,135], providing justification for trials evaluating antioxidant supplementation as adjunct anti-hypertensive therapy favoring blood pressure reduction.

Antihypertensive effects of vitamin C were hypothesized as early as 1946[136], and it has been proven that vitamin C enhances endothelial function through effects on nitric oxide production[75]. Most studies have demonstrated an inverse relation between vitamin C plasma levels and blood pressure, in normotensive and hypertensive populations[27,137]. However, evidence for blood pressure-lowering effects of vitamin C in clinical trials is still inconsistent. Nevertheless, laboratory[138,139] and human studies[140,141] have established biological plausibility for a clinical use of antioxidants concerning hypertension.

Taddei et al[142] made one of the first trials in 1998, where patients with essential hypertension received intra-arterial infusion of vitamin C, and showing that in essential hypertensive patients vitamin C significantly increased the vasodilation effect of the muscarinic agonist, acetylcholine, indicating that antioxidant vitamin C improves endothelium-dependent vasodilation in hypertensive patients. As ratifying evidence, On et al[143] in 2002 conducted a study that achieved similar results on endothelium dysfunction, using vitamin C as an adjunctive therapy to Amlodipine.

Despite the evidence points to the use of vitamin C as an adjunct in the treatment on essential hypertension, there is still lack of long-term studies that support its use. Up to date there are few trials that have used chronic supplementation. In a small randomized, double-blind controlled trial[144], patients were followed for 8 mo and were randomized to receive 500, 1000 and 2000 mg of vitamin C once daily. Results of this study showed a significant diminution of both, mean systolic blood pressure and diastolic blood pressure, with no differences between the increasing doses of vitamin C. Additionally, these effects were only seen during the first month of supplementation, suggesting only a short term benefit. Besides this, other trial aimed to study the effects of ascorbic acid on ambulatory blood pressure in elderly patients, showing that chronic supplementation of vitamin C (600 mg/daily) markedly reduced systolic blood pressure and pulse pressure in ambulatory patients[145]. Furthermore, this was accompanied by decreases of oxidative stress biomarkers such as levels of 8-isoprostane and malondialdehyde.

The strongest evidence of the possible role of vitamin C on hypertension treatment was handed by a recent a meta-analysis that included twenty-nine trials, concluding that in short-term trials, vitamin C supplementation reduces systolic and diastolic blood pressure. But it also highlights that long-term trials on the effects of vitamin C on blood pressure and clinical events are still needed to elucidate its true benefit[146].

Because supplementation made only with vitamin C has achieved inconsistent clinical outcomes, the scientific rational approach has led to the suggestion that the combined intake of antioxidants could achieve better clinical results. To prove this concept, a small randomized double-blind placebo-controlled trial was made including 38 subjects, 21 hypertensive and 17 normotensive[81]. Groups were assigned to receive in a crossover design placebo or a combination of antioxidants consisting of zinc, ascorbic acid, alpha-tocopherol and beta-carotene daily for 8 wk. Although it was a short-term following, this combined therapy of antioxidants showed that systolic blood pressure fell significantly on hypertensive subjects while been on the antioxidant phase compared with placebo. Additional evidence was given by another study aimed to evaluate the effect of short-term combined treatment with antioxidants vitamin C and E[95]: 30 essential hypertensive patients were assigned randomly either to vitamin C plus vitamin E or placebo for 8 wk. Results showed that parameters of flow-mediated dilation of the brachial artery and central pulse wave velocity were significantly improved after antioxidant supplementation, concluding that treatment with vitamins C and E has beneficial effects on endothelium-dependent vasodilation in untreated essential hypertensive patients.

Following the same consideration, recently a randomized double-blind placebo-controlled clinical trial was conducted to test the hypothesis that oral administration of vitamin C and E together causes decrease in blood pressure in patients with mild-to-moderate essential hypertension, 110 men with recent diagnosis of grade 1 essential hypertension were randomly assigned to receive either vitamin C (1 gr) plus Vitamin E (400 UI) daily or placebo for 8 wk. The results of this study, showed for the first time a specific association between oxidative-stress related parameters and blood pressure. Following administration of vitamins C plus E, patients with essential hypertension had significantly lower systolic, diastolic and mean arterial blood pressure[147].

According to the theoretical possibility of the role of antioxidants, further trials have been performed using different compounds with antioxidant activity. This is how Barrios et al[148] in 2002 conducted a patient crossover study with the aim to investigate the potential effect of NAC added to the Angiotensin-converting enzyme inhibitors (ACEI) antihypertensive action. A significant decrease in systolic and diastolic blood pressure was achieved with the combination of ACEI and NAC compared to ACEI-only period[148].

A more recent study tried the use of melatonin to evaluate its effectiveness as an adjunct for a combined treatment adding melatonin to standard anti-hypertensive drugs[149]. This study showed that combined therapy had better outcomes than standard therapy alone on essential hypertensive patients.

Although there is objective compelling evidence supporting the use of antioxidants in the management of hypertensive patients, there are also several studies that have not shown beneficial effects. As an example: Vitamin E[150], Coenzyme Q10[151], NAC[152] and vitamin C[153] have failed to obtain beneficial effects on clinical settings.

A summary of the antioxidant approaches as clinical interventions on essential hypertension is presented on Table 1.